aibioArtiva drops AlloNK, cuts about 94% of staff and weighs strategic alternatives
Tickers ARTV
The company ended AlloNK development after two patient deaths and durability data that did not meet its threshold. It reported about $319.1 million in cash, cash equivalents and investments at September 30, 2026, a preliminary figure.
Key facts
- Company
- Artiva Biotherapeutics, Inc. (NASDAQ: ARTV)
- News type
- Distress
- Primary source
- Artiva Biotherapeutics (SEC Form 8-K, Exhibit 99.1)
The decision
Artiva Biotherapeutics (Nasdaq: ARTV) said on October 27, 2026 that it will stop developing AlloNK, its allogeneic natural killer cell therapy, which was being tested with rituximab in rheumatoid arthritis and other B-cell-driven autoimmune diseases. The company says the planned Phase 3 pivotal trial will not start and that no more patients will be dosed in any ongoing AlloNK study.
The company says updated data still showed deep B cell depletion and clinical activity in line with earlier findings. The longer-term follow-up, however, did not show the level of durability of clinical response that the company says is needed to support continued development. Chief executive Fred Aslan, M.D. said the company had made "the difficult decision to discontinue development of AlloNK and to pursue strategic alternatives." The company also said it will no longer present previously announced clinical data at ACR Convergence 2026, and it is canceling its investor webcast set for November 9, 2026.
The two deaths
The release describes two Grade 5 events, the most severe grade, in the Phase 2a basket trial. The first was a fatal leukoencephalopathy in a participant who had received the study treatment with its protocol-specified lymphodepletion of cyclophosphamide and fludarabine. The investigator and an independent safety review assessed it as likely related to fludarabine-associated neurotoxicity. After the company reported the event, the FDA asked Artiva to pause enrollment and dosing in the Phase 2a study. The company also paused enrollment and dosing in the planned Phase 3 trial.
The second participant died suddenly about two months after starting treatment. The investigator assessed that death as unrelated to AlloNK or any other part of the regimen, and the release says the cause has not been determined. The company says it will publish details of the first case because fludarabine is widely used in cell therapy conditioning regimens. The release does not say when that publication will appear or whether it will address the second death.
Strategic alternatives and job cuts
Artiva's board is evaluating strategic alternatives intended to maximize stockholder value. These may include a merger, a business combination, a sale or licensing of assets, or dissolution and liquidation. Leerink Partners has been engaged as financial advisor. The release says there is no assurance the review will lead to any transaction or to a particular outcome.
The company is cutting its workforce by about 94%, which it says is intended to preserve capital while the review runs. The release does not give the cost of the cuts, the severance involved or the expected cost of closing out the clinical program. It also says the company will not provide further updates on the review unless the board approves a specific course of action, the process ends, or disclosure is required.
Cash and the 2025 losses
The release gives cash, cash equivalents and investments of about $319.1 million at September 30, 2026, described as preliminary and unaudited. The company says that figure may change when its quarterly report for the period is filed.
Its annual report for 2025, filed March 10, 2026, shows the spending behind the program. The net loss for 2025 was $83.9 million, up from $65.4 million in 2024. Research and development expense rose to $69.5 million from $50.3 million. Cash used in operations was $76.8 million in 2025, against $55.0 million in 2024. Revenue was $251,000 in 2024.
At December 31, 2025, cash and cash equivalents were $26.7 million, with $81.3 million in short-term investments. At June 30, 2026, cash and cash equivalents were $301.5 million, with $47.9 million in short-term investments. The September 30 figure combines cash and investments, while the June 30 figures are listed separately, so the two cannot be compared directly from these numbers.
What is left open
The release does not say how much of the $319.1 million the company expects to keep, distribute or use in a transaction. It also does not say whether the company intends to return cash to shareholders, and it names no partner or buyer.